Sharekhan's research report on Zydus Wellness
Zydus Wellness Limited’s (Zydus) Q4FY2022 performance was ahead of our expectation as it managed to post better-than-expected OPM to 22% despite sharp raw-material inflation. Revenue grew by ~6% with flat sales volume, while adjusted PAT stood flat at Rs. 133 crore. The company gained/maintained market share in most of the product categories (barring Complan). Focus is on sustained gain in market share in key channels. After two years of lull, summer products are gaining good traction with receding COVID-19 risk. Management is targeting double-digit revenue growth over the next two years. The company aims to achieve gross margin of close to 55% and OPM of 20%+ with better revenue mix.
Outlook
We maintain Buy on the stock with a revised PT of Rs. 2,250. The stock trades at 28.6x/22.8x its FY2023/FY2024 earnings, which is at a discount to some of the large peers.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!